Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

This study found little to no neutralizing capability following a 2-dose mRNA vaccine series against the omicron variant, and neutralizing capacity to any variant strain tested was lost by 8-months post 2-dose series. However, the mRNA booster dose eliminated the immune escape observed by the Omicron variant, following the 2-dose series.

Article activity feed

  1. SciScore for 10.1101/2022.01.26.22269819: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The Johns Hopkins University Institutional Review Board approved this study.
    Sex as a biological variablenot detected.
    Randomization1,3 For NT assays, 45 HWs were selected, prioritizing paired samples from TP1 and TP3, and others were selected at random.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.


    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations include that paired serum was only available post-dose2 and post-boost, and nABs titers were only performed on a small subset. The corresponding antibody trends between serum IgG and NT supports that despite only testing a subset of the participants for virus neutralization, all participants likely had robust broad NT post-boost, findings supported by recently published pre and post-boost studies.5 This study demonstrates that in paired samples an mRNA vaccine booster produces greater quantity and function of spike antibodies and NT as compared to primary SARS-CoV-2 mRNA immunization and was necessary to restore measurable NT to VOC. The booster dose eliminated the immune escape observed by Omicron following two-dose mRNA immunization. The variable NT to mRNA booster and whether breakthrough omicron infection boosts NT must be investigated to understand durable immunity against future VOC.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.